Market Whales and Their Recent Bets on VRTX Options
Alnylam Canada Signs LOI From Pan-Canadian Pharmaceutical Alliance For The Public Reimbursement Of AMVUTTRA For The Treatment Of Hereditary Transthyretin-Mediated Amyloidosis In Adults
Here's How Much $100 Invested In Gilead Sciences 20 Years Ago Would Be Worth Today
Consumer, Labor Groups Urge FTC to Block Catalent Sale to Novo Nordisk - Report
Vertex Coverage Resumed by UBS at Buy on Growth Potential
Looking Into Amgen's Recent Short Interest
This Gilead Sciences Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Gilead Sciences Analyst Ratings
Lilly, Gilead, Amgen Started at Outperform by Bernstein
Scotiabank Initiates Coverage On Vertex Pharmaceuticals With Sector Perform Rating, Announces Price Target of $480
Alnylam Pharmaceuticals Analyst Ratings
Regeneron Pharmaceuticals Analyst Ratings
Jasper Gains 11% on Data for Briquilimab in Urticaria
After eight weeks of selling off, the hedge fund bought back US stocks, achieving the fastest speed since 2021.
The US stock market is currently experiencing active buying and market growth, but the market's high valuation is a concerning issue that may trigger future adjustments.
Amgen Analyst Ratings
The bull market in US stocks will enter its third year. The three major stock index futures show mixed movements before the market opens. | Tonight's highlights
①The Nasdaq 100 index futures rose more than 0.4% in pre-market trading; ②Apple is set to launch a $2000 Vision headset as early as next year; ③Taiwan Semiconductor plans to establish more chip factories in Europe; ④GlaxoSmithKline's experimental drug for treating rhinitis has shown positive results.
Amgen Downgraded at Truist on MariTide Prospects for Obesity
Weight Loss Drugs Have One Big Issue; These Companies Want to Fix It
Cantor Fitzgerald Reiterates Neutral on Alnylam Pharmaceuticals, Maintains $220 Price Target
GSK Settles Majority Of Zantac Lawsuits, But Pipeline Doubts Remain